Investigating Immunotherapy Versus Best Supportive Care in Patients With CRC

February 4, 2019
Raymond Wadlow, MD

Raymond Wadlow, MD, discusses the results for the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer.

Raymond Wadlow, MD, a medical oncologist at Virginia Cancer Specialists, discusses results from the randomized phase II CCTG CO.26 trial investigating the use of immunotherapy versus best supportive care in heavily pretreated patients with colorectal cancer (CRC).

During a presentation at the 2019 Gastrointestinal Cancers Symposium, an overall survival benefit of approximately 2.5 months was found in patients with microsatellite-stable CRC.

This is exciting as it is the first finding, according to Wadlow, that shows a statistically significant improvement with a checkpoint inhibitor in the majority of this patient population.

See more from the 2019 Gastrointestinal Cancers Symposium.